Ragistomig

N/A

Report date: 2024/05/24 15:10:55

Base Information

Drug NameRagistomig

Drug Alias NameABL-503TJ-L14B/ABL503ABL503TJ-L14B

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionTumor necrosis factor receptor superfamily member 9 agonistsProgrammed death-ligand 1 blockers

TargetsTumor necrosis factor receptor superfamily member 9Programmed death-ligand 1

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesSouth Korea

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesI-Mab Biopharma Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesAbl Bio Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A